

DAFTAR PUSTAKA

- Adewoyin AS, Ogewale OA. 2015. Complication of allogenic blood transfusion: current approach to diagnosis and management. *International Blood ResRev* 3 (4): 135-51.
- Adriansyah R, Nafianty S, Rosdiana N, Lubis B. 2009. Reaksi Hemolitik Akibat Transfusi. *Maj Kedokteran Indonesia* 59(8): 387–391.
- Agrawal A, Mathur A, Dontula S, Jagannathan L, 2016. Red blood cell alloimmunization in multitransfused patients: a bicentric study in India. *Global journal of transfusion medicine* 9(1):12-15
- Ameen R, Al-Shemmari S, Al-Humood S, Chowdhury R, Al-Eyaadi O, Al-Bashir A, 2003. Erythrocyte alloimmunization and autoimmunization among transfusion-dependent Arab thalassemia patients. *Transfusion* 43(11):1604–10.
- Aplastic Anemia and MDS International Foundation. Aplastic Anemia. (2016a). <http://www.aamds.org/diseases/aplastic-anemia>.
- Aplastic Anemia and MDS International Foundation. Aplastic Anemia. Types. (2016b). <http://www.aamds.org/diseases/aplastic-anemia/types>.
- Arneja A, Salazar JE, Jiang W, Hendrickson JE, Zimring JC, Luckey CJ. 2016. Interleukin-6 receptor-alpha signaling drives anti-erythrocyte alloantibody production and T-follicular helper cell differentiation in a murine model of red blood cell alloimmunization. *Haematologica* 101:e440–404.
- Aygun B, Padmanabhan S, Paley C, Chandrasekaran V. 2002. Clinical significance of erythrocyte alloantibodies and autoantibodies in sickle cell patients who received transfusions. *Transfusion*. 42: 37-43.
- Azarkeivan A, Ansari S, Ahmadi MH, Hajibeigy B, Maghsudlu M, Nasizadeh S, et al. 2011. Blood transfusion and alloimmunization in patients with thalassemia: multicenter study. *Pediatr Hematol Oncol* 28(6):479–85.
- Barbara J. Viruses. 2004. *Vox Sang* 87: 595-7Wagner SJ.2004. Transfusion transmitted Bacterial Infection: risks, sources and interventions. *Vox Sang* 157-63
- Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. 1982. Proposals for the classification of the myelodysplastic syndromes. *Br J Haematol* 51 (2): 189-99.
- Beverung LM, Strouse JJ, Hulbert ML, Neville K, Liem RI, Inusa B, et al. 2015. Health-related quality of life in children with sickle cell anemia: impact of blood transfusion therapy. *Am J Hematol*; 90(2):139–43.

Bhattacharya P, Samanta E, Afroza N, Naik A, and Biswas R, 2018. An approach to incompatible cross-matched red cells: Our experience in a major regional blood transfusion center at Kolkata, Eastern India. *Asian J Transfus Sci*. 12(1): 51–56.

Bhuva DK, Vachhani JH. 2017. Red cell alloimmunization in repeatedly transfused patients. *Asian J Transfus Sci*, 11;115-20.

Bilwani F, Kakepoto GN, Adil SN, Usman M, Hassan F, Khurshid M, 2005. Frequency of irregular red cell alloantibodies in patients with thalassemia major: a bicenter study. *J Pak Med Assoc*; 563-565

Blajchman MA. 2004. Bacterial contamination of cellular blood components: risk, sources and control. *Vox Sang* S98-103.

Blaney, K.D., Howard, P.R. 2013. *Antibody Detection and Identification. Basic & Applied Concepts of Blood Banking and Transfusion Practices Third Edition.* . United States: Elsevier Mosby.p. 158- 187.

Brecher ME., 2005. Technical Manual. Fifteenth Edition. USA: *American Association of Blood Banks (AABB)*. p. 483-520.

Bukulmez H, Fife M, Tsoras M, Thompson SD, Twine NA, Woo P, et al. 2005. Tapasin gene polymorphism in systemic onset juvenile rheumatoid arthritis: a family-based case-control study. *Arthritis Res Ther* 7:R285–R290

Caamano J, Musante E, Contreras M, Uiloa H, Reyes C, Inalpil V, et al. 2015. Frequency and Specificity of Red Blood Cell Alloimmunization in Chilean Transfused Patients. *Transfusion Medicine and Hemotherapy* 42: 4-7.

Carson JL and Roger S. 2014. Transfusion strategies in hematologic and nonhematologic Disease. *American Society of Hematology*: 548-552.

Chao YH, Wu KH, Lu JJ, Shih MC, Peng CT, Chang CW. 2013. Redblood cell alloimmunization among Chinese patients with thalassaemia major in Taiwan. *Blood Transfus* 11(1):71–4.

Chiaroni J, Dettori I, Ferrera V, Legrand D, Touinssi M, Mercier P, et al. 2005. HLA-DRB1 polymorphism is associated with Kell immunization. *British Journal of Haematology* 132: 374-378.

Chu CC, Ho HT, Lee HL, Chan YS, Chang FJ, Wang CL, et al. 2009. Anti-“Mi(a)” immunization is associated with HLA-DRB1*0901. *Transfusion* 49: 472-8.

College of Physicians and Surgeons of Alberta. Crossmatch Techniques. <http://www.cpsa.ca/accreditation/alqep/transfusion-medicine> (Accessed: 13 August 2013)

Cortés BA. 2013. Anemia and transfusion of red blood cells. *Colomb Med.* 44(4): 236-41.

Corwin HL dan Carson JL. 2007. Blood transfusion- when is more really less? *N Engl J Med* 356: 16.

Cruz RO, Mota MA, Conti FM, Pereira RAA, Kutner JM, Aravechia MG, et al., 2011. Prevalence of erythrocyte alloimmunization in polytransfused patients. *Einstein (Sao Paulo)*. 2011 Jun;(2):173-8. Doi: 10.1590/S1679-45082011AO1777

C. Saygin, X. Jia, B. Hill, R. Dean, B. Pohlman, MR. Smith, et al., 2017. Impact of comorbidities on outcomes of elderly patients with diffuse large B-cell lymphoma. *American Journal of Hematology*, vol. 92, no. 10, pp. 989–996.

Dalimoenthe NZ, 2011. Dasar-Dasar Transfusi Darah. 1st Ed, Bandung, Balai Penerbit Fakultas Kedokteran Universitas Padjajaran, 27–38.

Dangsuwan P, Manchana T. 2010. Blood transfusion reduction with intravenous iron in gynecologic cancer patients receiving chemotherapy. *Gynecol Oncol* 116:522–5.

Das SS, Biswas, RN, Safi M, Zaman RU, 2021. Alloimmunization to erythrocyte antigens in patients receiving multiple blood transfusion: clinico-immunohematological and demographic risk factors and impact of extended red cell. *Glob J Transfus Med*;6:171-177

Datta SS, Mukherjee S, Talukder B, Bhattacharya P, Mukherjee K, 2015. Frequency of red cell alloimmunization and autoimmunization in thalassemia patients: a report from eastern India. *Advances in hematology*, 1-6

DeBaun MR, Gordon M, McKinstry RC, Noetzel MJ, White DA, Sarnaik SA, et al. 2014. Controlled trial of transfusions for silent cerebral infarcts in sickle cell anemia. *N Engl J Med*;371(8):699–710.

D. Sleep. 2015. Albumin and its application in drug delivery. *Expert Opinion on Drug Delivery*, vol. 12, no. 5, pp. 793–812.

E. Anne Stiene-Martin, Cheryl A. Lotspeich-Sreiningger, Jone A. 1998. Koepke. *Clinical Hematology Principle, procedures, Correlations*. second edition. Lippincott, New York: Raven publisher.

Eder AF dan Chambers LA. 2007. Noninfectious Complications of Blood Transfusion. *Arch Pathol Lab Med* 131: 708-18.

Elrahman SA dan Mirghani LB. 2017. Alloimmunization in Sudanese Leukemic Patients with Multiple Blood Transfusions. *Journal of Dental and Medical Sciences* 16 (3) 61-65.

F. Liu, J. Mu, and B. Xing., 2015. Recent advances on the development of pharmacotherapeutic agents on the basis of human serum albumin. *Current Pharmaceutical Design*, vol. 21, no. 14, pp. 866–1888.

Franchini M, Forni GL, Marano G, Cruciani M, Mengoli C, Pinto V, et al., 2019. Red blood cell alloimmunization in transfusion-dependent thalassemia: a systematic review. *Blood Transfus*; 17: 4-15.

Frenette PS, Atweh GF., 2007. Sickle cell disease: old discoveries, new concepts, and future promise. *J Clin Invest* 117: 850-858.

Galanello R, Sanna S, Perseu L, Sollaino MC, Satta S, et al. 2009. Amelioration of Sardinian beta0 thalassemia by genetic modifiers. *Blood* 114: 3935-3937.

Gantini RSE, Gatot D, Sofro AS, Soedarmono YSM., 2019. Research of red blood cell genotype antigen of the multitransfused patients: an effort to match the blood type in thalassemia patients as a model. *Indonesian Journal of Biotechnology and Biodiversity*, 3(2);75-80

Gerritsma JJ, Oomen I, Meinderts S, van der Schoot CE, Biemond BJ, van der Bom JG, et al., 2021. Back to base pairs: What is the genetic risk for red blood cell alloimmunization? *Bood Reviews*, 48:1-13

Goodnough LT, Brecher ME, Kanter MH, AuBuchon JP., 1999. Transfusion Medicine: First of two parts – blood transfusion. *N Engl J Med*. 340(6): 438-47.

Groh V, Steinle S, Bauer S, Spies T., 1998. Recognition of stress-induced MHC molecules by intestinal epithelial cd T cells. *Science* 279:1737–1740.

Guelsin GA, Rodrigues C, Visentainer JE, De Melo Campos P, Traina F, Gilli SC, et al., 2015. Molecular matching for Rh and K reduces red blood cell alloimmunization in patients with myelodysplastic syndrome. *Blood Transfus* 13(1):53–8

Gupta P, LeRoy SC, Luikart SD, Bateman A, Morrison VA., 1999. Long-term blood product transfusion support for patients with myelodysplastic syndromes (MDS): cost analysis and complications. *Leuk Res* 24 (2): 953-9.

Hall AM, Cairns LS, Altmann DM, Barker RN, Urbaniak SJ., 2005. Immune responses and tolerance to the RhD blood group protein in HLA transgenic mice. *Blood* 105:2175-9.

Handa A, Kukar N, Maharishi RN, Syal N, Arora H, 2020. Analysis of red cell alloimmunization in multi transfused patients at a tertiary care teaching hospital. *Journal of Family Medicine and Primary Care* 9(6):2907-2911.

Harmening DM. 2005. Modern blood banking and transfusion practice. 5th Ed., Book promotion & service. Philadelphia, F.A Davis Company 242–264.

Hebert PC., Tinmouth A., Carson J., 2007. Red cell Transfusion in Perioperative and Critically Ill Patients. In: Hillyer,C.D., Silberstein,L.E., Ness,P.M., Anderson,K.C., Roback,J.D. editors. Blood Banking and Transfusion Medicine. Second Edition. Philadelphia: Elsevier Inc. p. 445 – 454.

Hendrickson JE, Tormey CA. 2016. Understanding red blood cell alloimmunization triggers. *Hematol Am Soc Hematol EducProgram* 16(1):446–51.

Hoffbrand, P.A.H. Moss and J.E Pettit. 2011. Essential haematology. Sixth edition, Oxford West Sussex Hoboken: NJ Wiley-Blackwell.

Hoppe C, Klitz W, Vichinsky E, Styles L, 2009. HLA type and risk of alloimmunization in sickle cell disease. *Am J Hematol*, 84(7):462-464

Intansari US. Aspek imunologi transfusi darah: Kuliah Bank Darah dan Transfusi, program studi Subspesialis Patologi Klinik, Yogyakarta, Fakultas Kedokteran Universitas Gadjah Mada. 2012.

Irawaty, Rachmawati AM, Mansyur Arif. 2016. Characteriscis of Crossmatch Types in Compability Testing on Diagnosis and Blood Types Using Gel Method. *Indonesian Journal of Clinical Pathology and Medical Laboratory*. 23(1): 36–41.

Johnson ST, Pugh TM. Pretransfusion Compatibility Testing, 2004. In: Hillyer CD, Strauss RG, Luban NLC, editors. Handbook of Pediatric Transfusion Medicine. London, Elsevier Academic Press; 63–72.

Josephson CD, Su LL, Hillyer KL, Hillyer CD., 2007. Transfusion in the patient with sickle cell disease: a critical review of the literature and transfusion guidelines. *Transfus Med Rev* ;21(2):118–33.

Kahane I, Shifter A, Rachmilewitz EA. 1978. Cross-linking of red blood cell membrane proteins induced by oxidative stress in beta thalassemia. *FEBS Lett* 85:267-270.

K. Ghattass, R. Assah, M. El-Sabban, and H. Gali-Muhtasib. 2013. Targeting hypoxia for sensitization of tumors to radio- and chemotherapy. *Current Cancer Drug Targets*, vol. 13, no. 6, pp. 670–685, 2013.

Kangiwa U, Ibegbulam O, Ocheni S, Madu A, Mohammed N. 2015. Pattern and prevalence of alloimmunization in multiplytransfused patients with sickle cell disease in Nigeria. *Biomark Res* 3:26.

Kim HY, Cho EJ, Chun S, Kim KH, Cho D., 2019. Red Blood Cell Alloimmunization in Korean Patients With Myelodysplastic Syndrome and Liver Cirrhosis. *Annals of Laboratory Medicine*. 39 (2): 218-223.

Kirschmann DA, Duffin KL, Smith CE, Welply JK, Howard SC, Schwartz BD, et al. 1995. Naturally processed peptides from rheumatoid arthritis associated and non-associated HLA-DR alleles. *J Immunol* 155:5655-62.

Khusna N. Faktor Risiko Neonatus Bergolongan Darah A atau B Dari Ibu Bergolongan Darah O Terhadap Kejadian Hiperbilirubinemia. 2013. Hal:4-6.

Klein J, Sato A. 2000. The HLA system. *N Engl J Med*; 343:702–709.

Kormoczi GF and Mayr WR. Responder individuality in red blood cell alloimmunization. *Transfus med Hemother* 41:446-451

Kurniawan A, Atmakusuma D, Sukrisman L. 2016. Erythrocyte alloantibodi in transfusion dependent thalassemia patients: Proportion and related factors. *Biomedik*. 2016.

Lechler RI, Garden OA, Turka LA. 2003. The complementary roles of deletion and regulation in transplantation tolerance. *Nat Rev Immunol* 3:147–158.

Lin JS, Li-Hsuan Lee, Hsueng-Mei Liu, Ying-Ju Chen dan Tzeon-Jye Chiou. 2018. Association of *IL-6* C-572G Gene Polymorphism with Anti-E Production. *Transfus Med Hemother* 45:48–52.

Liu C dan Brenda JG. 2015. Redblood cekk transfusion For Hematologic Disorders. *American Society of Hematology*: 454-461.

Luban NLC. 2005. Transfusion Safety: where are we today? *Ann NY Acad Sci* 1054: 325-41.

Ma CS, Deenick EK, Batten M, Tangye SG. 2012. The origins, function, and regulation of T follicular helper cells. *J Exp Med* 209: 1241–1253.

Maharani EA dan Ganjar N. 2018. *Imunohematologi dan Bank Darah*. Edisi Pertama. Cetakan pertama. Kementerian Kesehatan Republik Indonesia. Jakarta.

Makroo RN, Bhatia A, Hegde V, Chowdhry M, Thakur UK, Rosamma NL, 2014. Antibody screening & identification in the general patient population at a tertiary care hospital in New Delhi. *Indian J Med Res*, 140(3): 401 405

Maluskova A, Mrazek F, Pauliskova M, Kovarova P, Koritska M, Jindra P, et al. 2017. Association of HLA-DRB1 and HLA-DQB1 with red-blood-cell alloimmunization in Czech population. *Vox Sanguinis*, 112:156-162

Martin J, Worthington J, Harris S, Martin S. 2009. The influence of class II transactivator and interleukin-6 polymorphism on the production of antibodies to donorhuman leucocyte antigen mismatches in renal allograftrecipients. *Int J Immunogenet* 36: 235–239.

Matteocci A, Pierelli L. 2014. Red blood cell alloimmunization in sickle cell disease and in thalassaemia: current status, future perspectives and potential role of molecular typing. *Vox Sang* ;106(3):197–208.

Merizka E. 2016. Profil Antigen Eritrosit dan Alloantibodi pada Pasien Talasemia di Pusat Talasemia Rumah Sakit Dr. Ciptomangunkusumo (RSCM). Program Studi Magister Ilmu Biomedik

Miah SS, Doha MA, Islam A, Quader MA, 2021. Crossmatch incompatibility, indwelling experience from a single center, Bangladesh. *Glob J Transfus Med*, 6(1):61-64

Mishra AK, Tiwari A. 2013. Iron overload in Beta thalassaemia major and intermedia patients. *Maedica (Buchar)* 8:328-332.

Mulyantari, Kadek dan I Wayan Putu Sutirta Yasa, MSi. 2016. Laboratorium Pra Transfusi Up Date. Udayana University Press.

National Heart, Lung, and Blood Institute, National Institutes of Health. 2012. Health Information for the Public. Health Topics. Aplastic Anemia. What is aplastic anemia? <https://www.nhlbi.nih.gov/health/health-topics/topics/aplastic/>.

Nickel RS, Hendrickson JE, Fasano RM, et al. 2016. Impact of red blood cell alloimmunization on sickle cell disease mortality: a case series. *Transfusion* 56(1):107-114.

Natukunda B, Schonewille H, Van De Watering L, 2010. Specificities of red cell alloantibodies in transfused Ugandans with different diseases. *Vox Sang* 2010; 98: 167-71.

Nester, T., AuBuchon, J.P. 2011. Hemotherapy Decisions and Their Outcomes. In: Roback, J.D., Grossman, B.J., Harris, T., Hillyer, C.D editors. Technical Manual. 17th Edition. USA: American Association of Blood Banks. p. 571-597.

Noizat-Pirenne F, Tournamille C, Bierling P, et al. 2006. Relative immunogenicity of Fya and K antigens in a Caucasian population, based on HLA class II restriction analysis. *Transfusion* 46:1328e33.

Papay P, Hackner K, Vogelsang H, Novacek G, Primas C, et al. 2012. High risk of transfusion-induced alloimmunization of patients with inflammatory bowel disease. *Am J Med*. 125.

Park SH, Nam E, Bang SM, Cho EK, Shin DB, Lee JH. 2008. A randomized trial of anemia correction with two different hemoglobin targets in the first-line chemotherapy of advanced gastric cancer. *Cancer Chemother Pharmacol* 62:1–9.

Philip J, Amit KB, Sumathi H, Neerja K. 2014. Red Blood Cell Alloimmunization in Multitransfused Patients in a Tertiary Care Center in Western India. *Lab Med Fall* 45(4): 320-326.

Picard C, Frassati C, Basire A, Buhler S, Galicher V, Ferrera V, et al. 2009. Positive association of DRB1*04 and DRB*15 alleles with Fya immunization in a Southern European population. *Transfusion*, 49:2412-17

Prati D. 2000. Benefits and complications of regular blood transfusion in patients with beta-thalassaemia major. *Vox Sang* 79:129-137.

Puppo F, Ghio M, Contini P, Brenci S, Bignardi D, Filaci G, et al. 1998. Immunoregulatory role of soluble HLA molecules: a new skin for an old subject? *Arch Immunol Ther Exp* 46:157–160.

Purwati D, Rofinda ZD, Husni. 2020. Karakteristik pasien transfusi darah dengan inkompatibilitas crossmatch di UTD RSUP Dr.M. Djamil Padang. *Jurnal Kesehatan Andalas*, 9(3):308

Rahajeng EP, Samad R, Muhiddin R. 2020. Identification of risk factors characteristics of transfusion reaction. *Indonesian Journal of Clinical Pathology and Medical Laboratory*, 26(3):266-71

Reyneke T. Comparison of the Gel (Diamed-ID Micro Typing System) and Tube Agglutination Cross-Match in Transfusion Medicine. South Africa: Tshwane University of Technology. 2007; 24–6.

Reviron D, Dettori I, Ferrera V, Legrand D, Touinssi M, Mercier P, et al. 2005. HLA-DRB1 alleles and Jk(a) immunization. *Transfusion* 45:956e9.

Rivella S.2015. β -Thalassemyas: paradigmatic diseases for scientific discoveries and development of innovative therapies. *Haematologica* 100: 418-430.

Rodrigues C, Sell A.M, Guelsin G.A.S, Higa T.T, Pagliarini e Silva S, Macedo L.C., et al. 2017. HLA polymorphisms and risk of red blood cell alloimmunisation in polytransfused patients with sickle cell anaemia. *Transfusion Medicine*;1-7

Rofinda ZD, Darwin E, Nasrul E, Wahid I, 2022. Erythrocyte antibody due to alloimmunization in repeated transfusion: a meta-analysis. *Open Acces Maced J Med Sci*, 10(F):257-262

Sahu S, Hemlata, and Anupam Verma. 2014. Adverse events related to blood transfusion. *Indian J Anaesth* 58(5): 543–551.

Scheller J, Chalaris A, Schmidt-Arras D, Rose-John S. 2011. The pro- and anti-inflammatory properties of the cytokine interleukin-6. *Biochim Biophys Acta* 1813: 878–888.

Schonewille H, Haak HL, van Zijl AM, 1999. Alloimmunization after blood transfusion in patients with hematologic and oncologic diseases. *Transfusion* 39:763-71.

Schonewille H, van de Watering LM, Loomans DS, Brand A. 2006. Red blood cell alloantibodies after transfusion: factors influencing incidence and specificity. *Transfusion* 46:250-6.

Schonewille H, Rene R.P. de Vries, and Anneke Brand. 2009. Alloimmune response after additional red blood cell antigenchallenge in immunized hematooncology patients. *Transfusion* 49 453-457.

Schonewille H, Doxiadis IIN, Levering WHBM, Roelen DL, Claas FHH, Brand A. 2014. HLA-DRB1 associations in individual with single and multiple clinically relevant red blood cell antibodies. *Transfusion* 54:1971-1980

Schrijvers D. 2011. Management of anemia in cancer patients: transfusions. *Oncologist*; 16(3), 12-18.

Sekeres MA. 2010. The epidemiology of myelodysplastic syndromes. *Hematol Oncol Clin North Am* 24 (2): 287-94.

Sirchia G, Zanella A, Parravicini A, et al. 1985. Red cell alloantibodies in thalassemia major. Results of an Italian cooperative study. *Transfusion* 25(2):110-2.

Sippert E, Visentainer J, Alves HV, Rodrigues C, Gilli SCO, Carvalho MA, et al. 2016. Red Blood Cell Alloimmunization in patients with sickle cell disease: correlation with HLA and cytokine gene polymorphism. *Transfusion* 00: 1-11.

Shamsian BS, Taghi AM, Shamshiri AR, Alavi S, Khojasteh, O. 2008. Frequency of red cell alloimmunization in patients with β -major thalassemia in an Iranian referral hospital. *Iran J Pediatr* 18: 149-153.

Singer ST, Wu V, Mignacca R, Kuypers FA, Morel P, et al. 2000. Alloimmunization and erythrocyte autoimmunization in transfusion-dependent thalassemia patients of predominantly Asian descent. *Blood* 96: 3369-3373.

Smart E and Armstrong B, 2020. Blood group systems. *ISBT Science Series*, 15:123-150

Soesilawati, P. 2011. Analisis Variasi HLA-DRB1 pada Jalur Imunogenetik Sekresi sIgA Sebagai Risiko Karies Gigi. *Disertasi*. Program Pasca Sarjana Universitas Airlangga. Surabaya.

Sood R, Makroo RN, Riana V, Rosamma NL. 2013. Detection of alloimmunization to ensure safer transfusion practice. *Asian J Transfus Sci* 2(2):135-9.

Spanos T, Karageorga M, Ladis V, et al. 1990. Red cell alloantibodies in patients with thalassemia. *Vox Sang* 58(1):50–5.

Stephen J, Cairns LS, Pickford WJ, et al. 2012. Identification, immunomodulatory activity, and immunogenicity of the major helper T-cell epitope on the K blood group antigen. *Blood* 119:5563-74

Stott LM, Barker RN, Urbaniak J. 2000. Identification of alloreactive T-cell epitopes on the Rhesus D protein. *Blood* 96:4011-9.

Sukati H, Watson HG, Urbaniak SJ, et al. 2007. Mapping helper T-cell epitopes on platelet membrane glycoprotein IIIa in chronic autoimmune thrombocytopenic purpura. *Blood* 109:4528-38.

Swarup CD, Dhot B, Kotwal J, Verma AK. Comparative Study of Blood Cross Matching using Conventional Tube and Gel Method. *MJAFI*, 2008; 64(2): 129–30.

Tangvarasittichai S. 2011. Thalassemia syndromes. In: Ikehara K. eds. Advances in the study of genetic disorders. InTech. Janeza Trdine 9, 51000 Rijeka, Croatia.; 101-148.

Tashreeg Awad elgied elamiean Ahmed, Leena babiker mirghani. 2016. Ceftriaxone induce immune hemolytic anemia in Sudanese patients. *American Journal of Research Communication* 4(9): 174-179.

Tatari-Calderone Z, Luban NLC, Vukmanovic S., 2014. Genetics of Transfusion Recipient Alloimmunization: Can Clues from Susceptibility to Autoimmunity Pave the Way?. *Transfus Med Hemother*, 41: 436-445.

Telen MJ, Afenyi-Annan A, Garrett ME, Combs MR, Orringer EP, Ashley-Koch AE. 2015. Alloimmunization in sickle cell disease: changing antibody specificities and association with chronic pain and decreased survival. *Transfusion* 55(6 Pt 2):1378-1387

Tiwari AK, Pandey P, Sharma J, Shailja K, Dixit S, Raina V. 2014. Incidence of clinically significant antibodies in patients and healthy blood donors: a prospective cross-sectional study from a tertiary healthcare center in India. *Transfus Apher Sci* 50(2):230–4

Traherne JA. 2008. Human MHC architecture and evolution: implications for disease association studies. *Int J Immunogenet* 35:179–192.

Tormey CA and Hendrickson JE, 2019. Transfusion-related red blood cell alloantibodies: induction and consequences. *Blood* 133(17):1821-1830.

Townsley, DM., Desmond, R., Dunbar, CE., & Young, NS. 2013. Pathophysiology and management of thrombocytopenia in bone marrow failure: Possible clinical

applications of TPO receptor agonists in aplastic anemia and myelodysplastic syndromes. *Int J Hematol*, 98, 48–55. <https://doi.org/10.1007/s12185-013-1352-6>.

Verduin EP, Brand A, Middelburg RA, Schonewille H. 2015. Female sex of older patients is an independent risk factor for red blood cell alloimmunization after transfusion. *Transfusion* 55:1478-85.

Vichinsky EP, Earles A, Johnson RA, et al. 1990. Alloimmunization in sickle-cell anemia and transfusion of racially unmatched blood. *N Engl J Med* ;322(23): 1617–21

Vichinsky E, Neumayr L, Trimble S, et al. 2014. Transfusion complications in thalassemia patients: a report from the Centers for Disease Control and Prevention (CME). *Transfusion* 54(4):972–81.

Vidushi, Sidhu M, Shah SN, 2020. Evaluation of incompatible crossmatch. *Glob J Transfus Med*, 5:68-2

Wahidiyat PA, Rahmartani LD, Putriasih SA. 2016. Pemakaian klinis produk darah pada kasus transfusi berulang. Divisi Hematologi-Onkologi, Departement Ilmu Kesehatan Anak, RSUPN Dr. Cipto Mangunkusumo.

Wahidiyat, PA dan Nitish BA. 2016. Transfusi Rasional pada Anak. *Sari Pediatri* 18(4):325-31.

Walter PB, Harmatz P, Vichinsky E. 2009. Iron metabolism and iron chelation in sickle cell disease. *Acta Haematol* 122: 174-183

Watkins T, Maria KS, dan Jeffrey MC. 2015. Transfusion Indications for Patients with Cancer. *Cancer Control* 22(1): 38-46.

Weinstein. 2016. Red Blood Cell Transfusion A Pocket Guide for the Clinician. Adapted from Red Blood Cell Transfusion: A clinical practice guideline from the AABB, Clinical Practice Guidelines from the AABB: Red blood cell transfusion thresholds and storage, and additional sources. *American Society of Hematology*.

Weiss ED, Chizhevsky V. Implementation of Gel Testing for Antibody Screening and Identification in a Community Hospital, a 3-Year Experience. *Lab Med*, 2005; 36(8): 489– 92.

Yazdanbakhsh K, Ware RE, Noizat-Pirenne F. 2012. Red blood cell alloimmunization in sickle cell disease: pathophysiology, risk factors, and transfusion management. *Blood*. 120: 528-537.

Zaman S, Chaurasia R, Chatterjee K, Thapliyal ML, 2014. Prevalence and specificity of RBC alloantibodies in Indian patients attending a tertiary care hospital. *Advances in Hematology*, 1-5

Zwaginga JJ, Ham SMv. 2017. Essential Immunology for Transfusion Medicine. Dalam: Murphy MF, Roberts DJ, Yazer MH, editor. Practical Transfusion Medicine. Edisi ke-5. Hoboken, NJ: John Wiley & Sons Inc hlm. 11-8.

Zou Y, Mirbaha F, Stastny P. 2006. Contact inhibition causes strong downregulation of expression of mica in human fibroblasts and decreased NK cell killing. *Hum Immunol* 67:183–187

Zundel WB, 2012. Pretransfusion testing. In: Harmening D, ed. Modern Blood Banking & Transfusion Practices. 6th ed. Philadelphia, PA: F.A. Davis Company, 241

